Application of transhepatic arterial interventional chemotherapy combined with targeted therapy and immunotherapy in patients with unresectable primary hepatocellular carcinoma
Application of transhepatic arterial interventional chemotherapy combined with targeted therapy and immunotherapy in patients with unresectable primary hepatocellular carcinoma
Objective To investigate the application effect of transcatheter arterial interventional chemotherapy[in-cluding transcatheter arterial chemoembolization(TACE)and/or hepatic arterial infusion chemotherapy(HAIC)]com-bined with targeted therapy and immunotherapy in patients with unresectable primary hepatocellular carcinoma(HCC).Method According to different treatment methods,50 HCC patients were divided into TACE and/or HAIC combined with targeted immunotherapy group(n=25,TACE and/or HAIC,targeted therapy,and immunotherapy)and standard treat-ment group(n=25,TACE and/or HAIC treatment).Objective response rate(ORR),disease control rate(DCR),progres-sion-free survival(PFS),overall survival(OS)and safety were observed.Result According to response evaluation crite-ria in solid tumor(RECIST)1.1,the ORR was 36％and the DCR was 76％.According to modified RECIST evaluation criteria,the ORR was 72％and the DCR was 76％.The overall survival and progression-free survival of patients in TACE and/or HAIC combined targeted therapy and immunotherapy group were better than those in standard therapy group,the differences were statistically significant(P＜0.05).Among the adverse reactions,grade 3-4 adverse reactions were neurop-athy(4％),and the others were mostly grade 1-2 manageable adverse reactions.Conclusion TACE and/or HAIC com-bined targeted therapy and immunotherapy can significantly improve the efficacy of unresectable HCC patients,prolong the survival time of patients,and have safety.
维普
万方数据